Brandes Investment Partners Adds $13M in Pfizer Inc. ($PFE)

Key Points

  • Brandes Investment Partners changed its Pfizer Inc. ($PFE) stake by 5.5% last quarter, boosting to 9,107,225 shares worth $240.39 million.
  • Wall Street's consensus rating on $PFE is Buy and an average price target of $29.19.
  • $PFE last traded around $26.39.

Brandes Investment Partners increased its position in Pfizer Inc. ($PFE) by 5.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,107,225 shares of Pfizer Inc. after buying 478,043 shares during the quarter. Brandes Investment Partners's holdings in Pfizer Inc. were worth $240.39 million as of its most recent filing.

Pfizer Inc. ($PFE) Stock

Last price$26.39
Market cap$149.38B
P/E ratio20.01
Forward P/E9.26
PEG ratio13.77
Beta0.29
52-week low$23.11
52-week high$28.75
50-day MA$26.40
200-day MA$25.86
Current ratio1.25
Quick ratio0.85
Debt-to-equity0.72

Pfizer Inc. Earnings

EPS (ttm)$1.31
Revenue (ttm)$63.32B
Revenue growth5.4%
Net margin11.8%
Return on equity8.3%
Next earningsJul 29, 2026

Pfizer Inc. Dividend

Annual dividend$1.72
Dividend yield656.00%
Payout ratio131.3%
Ex-dividend dateMay 8, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$29.19
High target$36.00
Low target$24.00
Analysts covering27

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersNew York, NY
CEODr. Albert Bourla D.V.M., Ph.D.
Employees75,000

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.